Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control ; volume:13 ; number:1 ; day:6 ; month:10 ; year:2023 ; pages:1-15 ; date:12.2023
Scientific reports ; 13, Heft 1 (6.10.2023), 1-15, 12.2023
- Urheber
-
Jabir, Majid S.
Al-Shammari, Ahmed M.
Ali, Zainab O.
Albukhaty, Salim
Sulaiman, Ghassan M.
Jawad, Sabrean F.
Hamzah, Sawsan S.
Syed, Asad
Elgorban, Abdallah M.
Eswaramoorthy, Rajalakshmanan
Zaghloul, Nouf S. S.
Al-Dulimi, Ali G.
Najm, Mazin A. A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-42299-4
- URN
-
urn:nbn:de:101:1-2024020113462131103572
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jabir, Majid S.
- Al-Shammari, Ahmed M.
- Ali, Zainab O.
- Albukhaty, Salim
- Sulaiman, Ghassan M.
- Jawad, Sabrean F.
- Hamzah, Sawsan S.
- Syed, Asad
- Elgorban, Abdallah M.
- Eswaramoorthy, Rajalakshmanan
- Zaghloul, Nouf S. S.
- Al-Dulimi, Ali G.
- Najm, Mazin A. A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Oncolytic virotherapy of glioblastoma
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Immune checkpoint modulation enhances oncolytic virotherapy
Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
Armed YB-1 dependent oncolytic adenoviruses for combined virotherapy and suicide gene therapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Effects of virus-induced immunogenic cues on oncolytic virotherapy
Oncolytic virotherapy of glioblastoma
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Immune checkpoint modulation enhances oncolytic virotherapy
Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
Armed YB-1 dependent oncolytic adenoviruses for combined virotherapy and suicide gene therapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy
Effects of virus-induced immunogenic cues on oncolytic virotherapy
Oncolytic virotherapy of glioblastoma
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
Immune checkpoint modulation enhances oncolytic virotherapy
Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Oncolytic Virotherapy of Canine and Feline Cancer
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
Armed YB-1 dependent oncolytic adenoviruses for combined virotherapy and suicide gene therapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Immunological aspects of YB-1-dependent oncolytic virotherapy
Overcoming the limitations of locally administered oncolytic virotherapy